Understanding the molecular mechanism of sequence dependent Tenofovir removal by HIV-1 reverse transcriptase: Differences in primer binding site versus polypurine tract

Antiviral Research

Volumn 95, Issue 2, 2012, Pages 93-103

  Iyidogan, Pinar ^a   Anderson, Karen S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral agents; Human immunodeficiency virus type 1; Nucleoside reverse transcriptase inhibitor; Reverse transcriptase; Tenofovir

Indexed keywords

ADENOSINE TRIPHOSPHATE; EFAVIRENZ; EMTRICITABINE; PURINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR;

ARTICLE; BINDING SITE; DNA SYNTHESIS; DRUG MECHANISM; DRUG STRUCTURE; LIFE CYCLE; NONHUMAN; PRIMER BINDING SITE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADENINE; ADENOSINE TRIPHOSPHATE; ANTI-HIV AGENTS; BINDING SITES; DNA REPAIR; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; PHOSPHONIC ACIDS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863832365     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.05.012     Document Type: Article

References (46)

1. Arion D., Kaushik N., McCormick S., Borkow G., Parniak M.A. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998, 37(45):15908-15917.
2. Barshop B.A., Adamson D.T., Vellom D.C., Rosen F., Epstein B.L., Seegmiller J.E. Luminescent immobilized enzyme test systems for inorganic pyrophosphate: assays using firefly luciferase and nicotinamide-mononucleotide adenylyl transferase or adenosine-5'-triphosphate sulfurylase. Anal. Biochem. 1991, 197(1):266-272.
3. Basavapathruni A., Bailey C.M., Anderson K.S. Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J. Biol. Chem. 2004, 279(8):6221-6224.
4. Boyer P.L., Imamichi T., Sarafianos S.G., Arnold E., Hughes S.H. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. J. Virol. 2004, 78(18):9987-9997.
5. Coffin J.M., Hughes S.H., Varmus H. Retroviruses 1997, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
6. Cruchaga C., Odriozola L., Andreola M., Tarrago-Litvak L., Martinez-Irujo J.J. Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors. Biochemistry 2005, 44(9):3535-3546.
7. Das K., Lewi P.J., Hughes S.H., Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 2005, 88(2):209-231.
8. Das K., Martinez S.E., Bauman J.D., Arnold E. HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat. Struct. Mol. Biol. 2012, 19(2):253-259.
9. De Clercq E. Antiretroviral drugs. Curr. Opin. Pharmacol. 2010, 10(5):507-515.
10. De Clercq E. Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era. Biochem. Pharmacol. 2012.
11. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25years after the discovery of HIV. Int. J. Antimicrob. Agents 2009, 33(4):307-320.
12. De Clercq E., Neyts J. Antiviral agents acting as DNA or RNA chain terminators. Handb. Exp. Pharmacol. 2009, (189):53-84.
13. FDA notifications, 2009. FDA approves generic combination of efavirenz, lamivudine & tenofovir. In: AIDS Alert, vol. 24, p. 130.
14. Feng J.Y., Anderson K.S. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry 1999, 38(1):55-63.
15. Feng J.Y., Ly J.K., Myrick F., Goodman D., White K.L., Svarovskaia E.S., Borroto-Esoda K., Miller M.D. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 2009, 6:44.
16. Hammer S.M., Kessler H.A., Saag M.S. Issues in combination antiretroviral therapy: a review. J. Acquir. Immune Defic. Syndr. 1994, 7(Suppl. 2):S24-S35. discussion S35-S37.
17. Han G.W., Kopka M.L., Cascio D., Grzeskowiak K., Dickerson R.E. Structure of a DNA analog of the primer for HIV-1 RT second strand synthesis. J. Mol. Biol. 1997, 269(5):811-826.
18. Hud N.V., Plavec J. A unified model for the origin of DNA sequence-directed curvature. Biopolymers 2003, 69(1):144-158.
19. Johnson A.A., Ray A.S., Hanes J., Suo Z., Colacino J.M., Anderson K.S., Johnson K.A. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 2001, 276(44):40847-40857.
20. Kati W.M., Johnson K.A., Jerva L.F., Anderson K.S. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 1992, 267(36):25988-25997.
21. Kerr S.G., Anderson K.S. RNA dependent DNA replication fidelity of HIV-1 reverse transcriptase: evidence of discrimination between DNA and RNA substrates. Biochemistry 1997, 36(46):14056-14063.
22. Killingley B., Pozniak A. The first once-daily single-tablet regimen for the treatment of HIV-infected patients. Drugs Today (Barc) 2007, 43(7):427-442.
23. Kopka M.L., Lavelle L., Han G.W., Ng H.L., Dickerson R.E. An unusual sugar conformation in the structure of an RNA/DNA decamer of the polypurine tract may affect recognition by RNase H. J. Mol. Biol. 2003, 334(4):653-665.
24. Marchand B., Gotte M. Site-specific footprinting reveals differences in the translocation status of HIV-1 reverse transcriptase. Implications for polymerase translocation and drug resistance. J. Biol. Chem. 2003, 278(37):35362-35372.
25. Marchand B., White K.L., Ly J.K., Margot N.A., Wang R., McDermott M., Miller M.D., Gotte M. Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir. Antimicrob. Agents Chemother. 2007, 51(8):2911-2919.
26. McConnell K.J., Beveridge D.L. Molecular dynamics simulations of B'-DNA: sequence effects on A-tract-induced bending and flexibility. J. Mol. Biol. 2001, 314(1):23-40.
27. Menendez-Arias L. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res. 2010, 85(1):210-231.
28. Meyer P.R., Matsuura S.E., Mian A.M., So A.G., Scott W.A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 1999, 4(1):35-43.
29. Meyer P.R., Matsuura S.E., So A.G., Scott W.A. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 1998, 95(23):13471-13476.
30. Meyer P.R., Smith A.J., Matsuura S.E., Scott W.A. Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase. J. Biol. Chem. 2004, 279(44):45389-45398.
31. Naeger L.K., Margot N.A., Miller M.D. Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine. Nucleosides, Nucleotides Nucleic Acids 2001, 20(4-7):635-639.
32. Naeger L.K., Margot N.A., Miller M.D. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 2002, 46(7):2179-2184.
33. Ng H.L., Kopka M.L., Dickerson R.E. The structure of a stable intermediate in the A↔B DNA helix transition. Proc. Natl. Acad. Sci. USA 2000, 97(5):2035-2039.
34. Radzio J., Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol. Pharmacol. 2008, 73(2):601-606.
35. Ray A.S., Murakami E., Basavapathruni A., Vaccaro J.A., Ulrich D., Chu C.K., Schinazi R.F., Anderson K.S. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 2003, 42(29):8831-8841.
36. Sarafianos S.G., Das K., Tantillo C., Clark A.D., Ding J., Whitcomb J.M., Boyer P.L., Hughes S.H., Arnold E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J. 2001, 20(6):1449-1461.
37. Sarafianos S.G., Marchand B., Das K., Himmel D.M., Parniak M.A., Hughes S.H., Arnold E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 2009, 385(3):693-713.
38. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267(5200):988-993.
39. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J., Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. 1999, 341(25):1865-1873.
40. Tantillo C., Ding J., Jacobo-Molina A., Nanni R.G., Boyer P.L., Hughes S.H., Pauwels R., Andries K., Janssen P.A., Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 1994, 243(3):369-387.
41. Tsibris A.M., Hirsch M.S. Antiretroviral therapy in the clinic. J. Virol. 2010, 84(11):5458-5464.
42. Tu X., Das K., Han Q., Bauman J.D., Clark A.D., Hou X., Frenkel Y.V., Gaffney B.L., Jones R.A., Boyer P.L., Hughes S.H., Sarafianos S.G., Arnold E. Structural basis of HIV-1 resistance to AZT by excision. Nat. Struct. Mol. Biol. 2010, 17(10):1202-1209.
43. Tuske S., Sarafianos S.G., Clark A.D., Ding J., Naeger L.K., White K.L., Miller M.D., Gibbs C.S., Boyer P.L., Clark P., Wang G., Gaffney B.L., Jones R.A., Jerina D.M., Hughes S.H., Arnold E. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol. 2004, 11(5):469-474.
44. White K.L., Chen J.M., Margot N.A., Wrin T., Petropoulos C.J., Naeger L.K., Swaminathan S., Miller M.D. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob. Agents Chemother. 2004, 48(3):992-1003.
45. White K.L., Margot N.A., Wrin T., Petropoulos C.J., Miller M.D., Naeger L.K. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 2002, 46(11):3437-3446.
46. Zhan P., Liu X., Li Z., Pannecouque C., De Clercq E. Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem. 2009, 16(29):3903-3917.